A7b. @NBOCA_CEU now collects genomic profiling data (RAS/BRAF) to ensure targeted & personalised systemic treatments in patients with stage IV disease #IMPACTimoact. Even MMR status makes a difference to treatment options in patients with stage IV disease. #NBOCAQualityImp
@IMPACT_ReCaP by @CliffRach
4 stage prospective study (n=891 pts) capturing MDT decision-making in rectal ca Tx during COVID-19.
Stoma rate in 1st wave >80%. Short course RTx usage increasing during pandemic. SCRT seems to have lower stoma rate & comps, but LT oncology unclear
Development of robotic curricula for #colorectalsurgery is essential. @M_GomezRuiz highlights the Colorobotica programme @rocs2021 @escp_tweets#ROCS2021
🤖Standardised stepwise program
🤖Prerequisite criteria
🤖Regular objective assessment
🤖High volume & access is 🔑
*CLOSING DATE*
As life returns a little more to normality - Just a quick reminder that patients diagnosed after today will no longer be eligible for inclusion @IMPACT_ReCaP
REDCap will remain open however for data entry!
@ACPGBI@Dukes_Club#collaborate
@IMPACT_ReCaP@mikelim75@ACPGBI@RCSnews Much more to come from this important piece of work as we follow the cohort over the next few years. Thank you also to our funders @BowelResearch and also @IMPACTaudit for supporting and facilitating the rapid rollout of this study
Delighted to share the results of the first 500 patients entered into our database! A snapshot of how rectal cancer management changed post lockdown
A massive Thankyou to all of our collaborators for their ongoing work!
@ACPGBI@RCSnews#collaboration
https://t.co/daixdZY9wX
Happy New Year to all of our @IMPACT_ReCaP collaborators! Another opportunity to say a massive Thankyou for all of your hard work during 2020 to support our study!
And a reminder that our database is still open for patient entry...
@ACPGBI@Dukes_Club@RCSnews